Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review

被引：24

作者：

Cattrini, Carlo ^{[1
,2
,3
]}

Caffo, Orazio ^{[4
]}

De Giorgi, Ugo ^{[5
]}

Mennitto, Alessia ^{[1
,2
]}

Gennari, Alessandra ^{[1
,2
]}

Olmos, David ^{[6
]}

Castro, Elena ^{[7
,8
]}

机构：

[1] Maggiore Carita Univ Hosp, Dept Med Oncol, I-28100 Novara, Italy

[2] Univ Eastern Piedmont UPO, Dept Translat Med DIMET, Med Oncol, I-28100 Novara, Italy

[3] Univ Genoa, Dept Internal Med & Med Specialties DIMI, I-16132 Genoa, Italy

[4] Santa Chiara Hosp, Dept Med Oncol, I-38122 Trento, Italy

[5] IRCCS, Dept Oncol, Ist Romagnolo Studio Tumori IRST Dino Amadori, I-47014 Meldola, Italy

[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp Octubre Imas12 12, Dept Med Oncol, Madrid 28041, Spain

[7] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga 29010, Spain

[8] Hosp Univ Virgen de la Victoria & Reg Malaga, UGCI Med Oncol, Malaga 29010, Spain

来源：

CANCERS | 2022年 / 14卷 / 07期

关键词：

nonmetastatic castration-resistant prostate cancer; nmCRPC; androgen-receptor signaling inhibitors; conventional imaging; PSMA-PET; apalutamide; darolutamide; enzalutamide; METASTASIS-FREE SURVIVAL; ANTIANDROGEN THERAPY; ABIRATERONE ACETATE; ANDROGEN BLOCKADE; DOSE-ESCALATION; PLUS PREDNISONE; PHASE-3; MEN; BICALUTAMIDE; DOCETAXEL;

D O I：

10.3390/cancers14071792

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Apalutamide, darolutamide and enzalutamide are androgen-receptor signaling inhibitors proved to be useful in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Although computed tomography and bone scans have been used to identify patients with nmCRPC in pivotal trials, currently, novel imaging techniques are widely used to stage patients, and they can detect metastases in many men with nmCRPC who are negative to conventional imaging. This review aims at discussing the role of apalutamide, darolutamide and enzalutamide in nmCRPC and the clinical implications of novel imaging techniques during treatment choice. Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical progression during treatment with androgen-deprivation therapy (ADT) without signs of radiographic progression according to conventional imaging. The SPARTAN, ARAMIS and PROSPER trials showed that apalutamide, darolutamide and enzalutamide, respectively, prolong metastasis-free survival (MFS) and overall survival (OS) of nmCRPC patients with a short PSA doubling time, and these antiandrogens have been recently introduced in clinical practice as a new standard of care. No direct comparison of these three agents has been conducted to support treatment choice. In addition, a significant proportion of nmCRPC on conventional imaging is classified as metastatic with new imaging modalities such as the prostate-specific membrane antigen positron emission tomography (PSMA-PET). Some experts posit that these "new metastatic" patients should be treated as mCRPC, resizing the impact of nmCRPC trials, whereas other authors suggest that they should be treated as nmCRPC patients, based on the design of pivotal trials. This review discusses the most convincing evidence regarding the use of novel antiandrogens in patients with nmCRPC and the implications of novel imaging techniques for treatment selection.

引用

页数：15

共 80 条

[1] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J].

Abida, Wassim ;

Cheng, Michael L. ;

Armenia, Joshua ;

Middha, Sumit ;

Autio, Karen A. ;

Vargas, Hebert Alberto ;

Rathkopf, Dana ;

Morris, Michael J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Carbone, Emily ;

Barnett, Ethan S. ;

Hullings, Melanie ;

Hechtman, Jaclyn F. ;

Zehir, Ahmet ;

Shia, Jinru ;

Jonsson, Philip ;

Stadler, Zsofia K. ;

Srinivasan, Preethi ;

Laudone, Vincent P. ;

Reuter, Victor ;

Wolchok, Jedd D. ;

Socci, Nicholas D. ;

Taylor, Barry S. ;

Berger, Michael F. ;

Kantoff, Philip W. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Solit, David B. ;

Gopalan, Anuradha ;

Scher, Howard I. .

JAMA ONCOLOGY, 2019, 5 (04) :471-478

[2] Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients [J].

Afshar-Oromieh, Ali ;

Holland-Letz, Tim ;

Giesel, Frederik L. ;

Kratochwil, Clemens ;

Mier, Walter ;

Haufe, Sabine ;

Debus, Nils ;

Eder, Matthias ;

Eisenhut, Michael ;

Schaefer, Martin ;

Neels, Oliver ;

Hohenfellner, Markus ;

Kopka, Klaus ;

Kauczor, Hans-Ulrich ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) :1258-1268

[3] Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study [J].

Aggarwal, Rahul ;

Huang, Jiaoti ;

Alumkal, Joshi J. ;

Zhang, Li ;

Feng, Felix Y. ;

Thomas, George V. ;

Weinstein, Alana S. ;

Friedl, Verena ;

Zhang, Can ;

Witte, Owen N. ;

Lloyd, Paul ;

Gleave, Martin ;

Evans, Christopher P. ;

Youngren, Jack ;

Beer, Tomasz M. ;

Rettig, Matthew ;

Wong, Christopher K. ;

True, Lawrence ;

Foye, Adam ;

Playdle, Denise ;

Ryan, Charles J. ;

Lara, Primo ;

Chi, Kim N. ;

Uzunangelov, Vlado ;

Sokolov, Artem ;

Newton, Yulia ;

Beltran, Himisha ;

Demichelis, Francesca ;

Rubin, Mark A. ;

Stuart, Joshua M. ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2492-+

[4] Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Zhu, Yezi ;

Silberstein, John L. ;

Taylor, Maritza N. ;

Maughan, Benjamin L. ;

Denmeade, Samuel R. ;

Pienta, Kenneth J. ;

Paller, Channing J. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2149-+

[5] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

[6] The long tail of oncogenic drivers in prostate cancer [J].

Armenia, Joshua ;

Wankowicz, Stephanie A. M. ;

Liu, David ;

Gao, Jianjiong ;

Kundra, Ritika ;

Reznik, Ed ;

Chatila, Walid K. ;

Chakravarty, Debyani ;

Han, G. Celine ;

Coleman, Ilsa ;

Montgomery, Bruce ;

Pritchard, Colin ;

Morrissey, Colm ;

Barbieri, Christopher E. ;

Beltran, Himisha ;

Sboner, Andrea ;

Zafeiriou, Zafeiris ;

Miranda, Susana ;

Bielski, Craig M. ;

Penson, Alexander V. ;

Tolonen, Charlotte ;

Huang, Franklin W. ;

Robinson, Dan ;

Wu, Yi Mi ;

Lonigro, Robert ;

Garraway, Levi A. ;

Demichelis, Francesca ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen ;

Abida, Wassim ;

Taylor, Barry S. ;

Scher, Howard I. ;

Nelson, Peter S. ;

de Bono, Johann S. ;

Rubin, Mark A. ;

Sawyers, Charles L. ;

Chinnaiyan, Arul M. ;

Schultz, Nikolaus ;

Van Allen, Eliezer M. .

NATURE GENETICS, 2018, 50 (05) :645-+

[7] Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Luo, Jun ;

Nanus, David M. ;

Giannakakou, Paraskevi ;

Szmulewitz, Russell Z. ;

Danila, Daniel C. ;

Healy, Patrick ;

Anand, Monika ;

Rothwell, Colin J. ;

Rasmussen, Julia ;

Thornburg, Blair ;

Berry, William R. ;

Wilder, Rhonda S. ;

Lu, Changxue ;

Chen, Yan ;

Silberstein, John L. ;

Kemeny, Gabor ;

Galletti, Giuseppe ;

Somarelli, Jason A. ;

Gupta, Santosh ;

Gregory, Simon G. ;

Scher, Howard I. ;

Dittamore, Ryan ;

Tagawa, Scott T. ;

Antonarakis, Emmanuel S. ;

George, Daniel J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1120-+

[8] Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [J].

Attard, Gerhardt ;

Murphy, Laura ;

Clarke, Noel W. ;

Cross, William ;

Jones, Robert J. ;

Parker, Christopher C. ;

Gillessen, Silke ;

Cook, Adrian ;

Brawley, Chris ;

Amos, Claire L. ;

Atako, Nafisah ;

Pugh, Cheryl ;

Buckner, Michelle ;

Chowdhury, Simon ;

Malik, Zafar ;

Russell, J. Martin ;

Gilson, Clare ;

Rush, Hannah ;

Bowen, Jo ;

Lydon, Anna ;

Pedley, Ian ;

O'Sullivan, Joe M. ;

Birtle, Alison ;

Gale, Joanna ;

Srihari, Narayanan ;

Thomas, Carys ;

Tanguay, Jacob ;

Wagstaff, John ;

Das, Prantik ;

Gray, Emma ;

Alzoueb, Mymoona ;

Parikh, Omi ;

Robinson, Angus ;

Syndikus, Isabel ;

Wylie, James ;

Zarkar, Anjali ;

Thalmann, George ;

de Bono, Johann S. ;

Dearnaley, David P. ;

Mason, Malcolm D. ;

Gilbert, Duncan ;

Langley, Ruth E. ;

Millman, Robin ;

Matheson, David ;

Sydes, Matthew R. ;

Brown, Louise C. ;

Parmar, Mahesh K. B. ;

James, Nicholas D. .

LANCET, 2022, 399 (10323) :447-460

[9]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[10] Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence [J].

Boorjian, Stephen A. ;

Thompson, R. Houston ;

Tollefson, Matthew K. ;

Rangel, Laureano J. ;

Bergstralh, Eric J. ;

Blute, Michael L. ;

Karnes, R. Jeffrey .

EUROPEAN UROLOGY, 2011, 59 (06) :893-899

← 1 2 3 4 5 6 7 8 →